Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers analysis to compare the safety and efficacy of biodegradable polymer stents (BP-DES) to the durable polymer Resolute Integrity drug-eluting stent (DP-DES) from Medtronic. At one year, patients with coronary artery disease who were treated with a biodegradable polymer stent showed no clinical benefits over patients treated with Resolute Integrity.

November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel Drug-Filled Stent (DFS) from the ...

Medtronic plc presented new positive data from two large registries aimed at evaluating 30-day clinical performance outcomes for the self-expanding, recapturable and repositionable CoreValve Evolut R System in “real-world” severe aortic stenosis patient populations at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting.

SecurityScorecard, a security rating and continuous risk monitoring platform, released its 2016 Healthcare Industry Cybersecurity Report in October. The report is a comprehensive analysis exposing alarming cybersecurity vulnerabilities across 700 healthcare organizations including medical treatment facilities, health insurance agencies and healthcare manufacturing companies. Security breaches in this industry pose devastating consequences, according to the company, because they can render an entire system or network inoperable, creating a life or death situation that needs immediate attention.

White coat hypertension, where patients have high blood pressure readings in a medical setting but normal blood pressure outside the doctor’s office, is most likely an innocuous condition that is not a predictor of heart disease or stroke — except in a small group of older patients. This conclusion was drawn from a study published recently in the Journal of the American College of Cardiology.

Optical coherence tomography (OCT) provides safe and improved guidance for patients undergoing percutaneous coronary intervention to treat coronary artery disease, according to results from the ILLUMIEN III: OPTIMIZE PCI trial. The trial sought to determine whether a novel OCT-based stent sizing strategy would result in a comparable or superior minimal stent area (MSA) as achieved with former stent implant imaging techniques.

Mitralign will present data on its Trialign Tricuspid Repair system at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) conference, which will be held in Washington, D.C. Oct. 29-Nov. 2. The company will be presenting 30-day data from SCOUT I, a U.S. multi-center, early feasibility study (EFS).